Angioedema associated with aspirin and rofecoxib

Annals of Pharmacotherapy

Volumn 39, Issue 5, 2005, Pages 944-948

  Marshall, Leisa L ^a  

^a MERCER UNIVERSITY   (United States)

Author keywords

Angioedema; Aspirin; Celecoxib; Cyclooxygenase 2 inhibitor; Rofecoxib; Valdecoxib

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; COTRIMOXAZOLE; DIPHENHYDRAMINE; FEXOFENADINE; LORATADINE; NAPHAZOLINE; OLOPATADINE; PARACETAMOL; PREDNISONE; ROFECOXIB; TRIAMCINOLONE ACETONIDE;

ADULT; ANAMNESIS; ANGIONEUROTIC EDEMA; ANTIBIOTIC THERAPY; ARTICLE; BETA HEMOLYTIC STREPTOCOCCUS; CASE REPORT; CLINICAL FEATURE; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; FEMALE; HUMAN; JAW DISEASE; LIP DISEASE; MOUTH DISEASE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RATING SCALE; SKIN TEST; SORE THROAT; THROAT CULTURE;

ADULT; AGED; ANGIONEUROTIC EDEMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; LACTONES; MALE; MIDDLE AGED; SULFONES;

EID: 17644411448     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E546     Document Type: Article

References (26)

1. Stevenson DD. Anaphylactic and anaphylactoid reactions to aspirin and other nonsteroidal anti-inflammatory drugs. Immunol Allergy Clin North Am 2001;21:745-68.
2. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
3. Grimm V, Rakoski J, Ring J. Urticaria and angioedema induced by COX-2 inhibitors (letter). J Allergy Clin Immunol 2002;109:370.
4. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Cutaneous reactions to aspirin and nonsteroidal antiinflammatory drugs. Clin Rev Allergy Immunol 2003;24:125-36.
5. Stevenson DD. Aspirin and NSAID sensitivity. Immunol Allergy Clin North Am 2004;24:491-505,vii.
6. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F, Perez CR. Tolerability of new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol 2001;87:201-4.
7. Martinez B, Mathews AW, Lublin JS, Winslow R. Merck pulls Vioxx from market after link to heart problems. Wall Street Journal 2004 (Oct 1):A1, A12.
8. Package insert. Bextra (valdecoxib). New York: Pfizer, May 2004.
9. Package insert. Celebrex (celecoxib). New York: Pfizer, January 2004.
10. Package insert. Vioxx (rofecoxib). Whitehouse Station, NJ: Merck, August 2004.
11. Hinrichs R, Ritzkowsky A, Hunzelmann N, Krieg T, Scharffetter-Kochanek K. Rofecoxib as an alternative in aspirin hypersensitivity. Allergy 2001;56:789.
12. Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. Clin Immunol 2001;108:47-51.
13. Quiralte J, San Pedro BS, Florido JF. Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. Ann Allergy Asthma Immunol 2002;89:63-6.
14. Szczeklik A, Nizankowska E, Bochenek G, Nagraba K, Mejza F, Swierczynska M. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Experimental Allergy 2000;31:219-25.
15. Martin-Garcia C, Hinojosa M, Berges P, Camacho E, Garcia-Rodriguez R, Alfaya T, et al. Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest 2002;121:1812-7.
16. Yoshida S, Ishizaki Y, Onuma K, Shoju T, Hakagawa H, Amayasu H. Selective cyclo-oxygenase 2 inhibitor in patients with aspirin-induced asthma (letter). J Allergy Clin Immunol 2000;106:1201-2.
17. Fernandez-Melendez S, Miranda A, Carmona MJ, Diaz J, Barcelo JM, Vega JM, et al. Tolerance of rofecoxib in patients with adverse reactions to nonsteroidal anti-inflammatory drugs (abstract). J Allergy Clin Immunol 2002;109(1 pt 2):S140.
18. Zembowicz A, Mastalerz L, Setkowicz M, Radziszewski W, Szczeklik A. Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs. Arch Dermatol 2003;139:1577-82.
19. Marks F, Jarrell K, Fischer R. Successful use of cyclooxygenase-2 inhibitor in a patient with aspirin-induced asthma. South Med J 2001;94:256-7.
20. Nettis E, Di Paola R, Ferrannini A, Tursi A. Tolerability of rofecoxib in patients with cutaneous adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002;88:331-4.
21. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Valdecoxib is a safe alternative drug for NSAID-sensitive patients with cutaneous reactions (abstract 411). J Allergy Clin Immunol 2003;111(2 suppl):s171.
22. Perrone MR, Artesani MC, Viola M, Gaeta F, Caringi M, Quaratino D, et al. Tolerability of rofecoxib in patients with adverse reactions to non-steroidal anti-inflammatory drugs: a study of 216 patients and literature review. Int Arch Allergy Immunol 2003;132:82-6.
23. Asero R. Tolerability of rofecoxib. Allergy 2001;56:916-7.
24. Schellenberg RR, Isserow SH. Anaphylactoid reaction to a cyclooxygenase-2 inhibitor in a patient who had a reaction to a cyclooxygenase-1 inhibitor (letter). N Engl J Med 2001;345:1856.
25. Kelkar PS, Butterfield JH, Teaford HG. Urticaria and angioedema from cyclooxygenase-2 inhibitors. J Rheumatol 2001;28:2553-4.
26. Grob M, Pichler W, Wuthrich B. Anaphylaxis to celecoxib. Allergy 2002;57:264-5.